Market cap
$231 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -2,774.19 | -335.68 | -247.49 |
| Net Profit | 113.93 | 636.01 | -3,611.70 | -333.44 | -256.28 |
| EPS | 107.73 | 151.29 | -2,021.81 | -255.01 | -218.48 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| 157.02 | 167.89 | -- | 352.58 | -5.31 |
| Return on Capital
| 454.04 | 218.74 | -- | 1,414.79 | 3.28 |
| Return on Assets
| -161.62 | -121.50 | -597.52 | -434.34 | 3.06 |
| Debt to Equity (x)
| -- | -- | 0.00 | -0.46 | -2.34 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
1,414.79
|
3.28
|
-55.94
|
-104.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
352.58
|
-5.31
|
123.78
|
532.99
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-597.52
Lower than Peers by 566.54
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
-597.52
|
-434.34
|
3.06
|
-53.59
|
-48.57
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-2,774.19
Lower than Peers by 2,773.39
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
-2,774.19
|
-4,989.50
|
127.63
|
12.06
|
45.57
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-3,611.70
Lower than Peers by 3,604.40
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
-3,611.70
|
-20,492.68
|
104.80
|
6.55
|
35.66
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
-2,021.81
Lower than Peers by 2,036.46
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
-2,021.81
|
-139.83
|
1.04
|
0.23
|
0.36
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
39.94
Higher than Peers by 50.11
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
39.94
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
-0.46
|
-2.34
|
-2.88
|
-3.68
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
20.14
Higher than Peers by 14.34
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
20.14
|
36.29
|
7.85
|
12.57
|
29.15
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
20.14
Higher than Peers by 14.45
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
20.14
|
--
|
--
|
--
|
31.34
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
--
|
1.32
|
-2.62
|
-3.33
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
--
|
--
|
-35,570.29
|
-129,453.64
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
75,400.57
|
27,741.74
|
16,357.30
|
60,557.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
-0.15
|
11.69
|
-1.33
|
-0.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
2.68
Lower than Peers by 2.50
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
2.68
|
-0.32
|
-0.65
|
-1.41
|
-0.42
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
2.60
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
2.60
|
-0.09
|
9.19
|
-3.74
|
-1.87
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
231
Higher than Peers by 85
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
|
231
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|